Trial reportNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2012
Developing and validating a human laboratory model to screen medications for smoking cessation.
Trial report in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Effects of varenicline and bupropion on laboratory smoking outcomes: Meta-analysis of randomized, placebo-controlled human laboratory studies.Addiction biology · 2022Pooled it
- Effects of experimental negative affect manipulations on ad libitum smoking: a meta-analysis.Addiction (Abingdon, England) · 2015Pooled it
- Once-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Combined Working Memory Training and Transcranial Magnetic Stimulation Demonstrates Low Feasibility and Potentially Worse Outcomes on Delay to Smoking and Cognitive Tasks: A Randomized 2 × 2 Factorial Design Pilot and Feasibility Study.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2022Trial
- Combination Lorcaserin and Nicotine Patch for Smoking Cessation Without Weight Gain.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2020Trial
- The effects of mindfulness-based yogic breathing on craving, affect, and smoking behavior.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2020Trial
- Pain characteristics and nicotine deprivation as predictors of performance during a laboratory paradigm of smoking cessation.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2020Trial
- The influence of gender and oxytocin on stress reactivity, cigarette craving, and smoking in a randomized, placebo-controlled laboratory relapse paradigm.Psychopharmacology · 2020Trial
- Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.Addiction biology · 2020Trial
- Targeting neuroinflammation with minocycline in heavy drinkers.Psychopharmacology · 2019Trial
- Lack of effect of transcranial direct current stimulation (tDCS) on short-term smoking cessation: Results of a randomized, sham-controlled clinical trial.Drug and alcohol dependence · 2019Trial
- Momentary changes in craving predict smoking lapse behavior: a laboratory study.Psychopharmacology · 2018Trial
- Second Generation Electronic Nicotine Delivery System Vape Pen Exposure Generalizes as a Smoking Cue.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2018Trial
- Reduction of smoking urges with intranasal insulin: a randomized, crossover, placebo-controlled clinical trial.Molecular psychiatry · 2017Trial
- Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers.Pharmacology, biochemistry, and behavior · 2015Trial
- A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessation.Journal of psychopharmacology (Oxford, England) · 2015Trial
- Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.The American journal of drug and alcohol abuse · 2015Trial
- Predictors of smoking lapse in a human laboratory paradigm.Psychopharmacology · 2014Trial
- Resisting the urge to smoke and craving during a smoking quit attempt on varenicline: results from a pilot fMRI study.The American journal of drug and alcohol abuse · 2013Trial
- Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
introductionTo facilitate translational work in medications development for smoking cessation, we have developed a human laboratory analogue of smoking lapse behavior. Our paradigm models 2 critical features of smoking lapse: the ability to resist the first cigarette and subsequent ad libitum smoking. In this paper we present the results of 2 studies designed to develop and validate the effect of nicotine deprivation on smoking lapse behavior.
methodsStudy 1 (n = 30) was designed to develop the model parameters by examining varying levels of nicotine deprivation (1, 6, and 18 hr; within-subject) and identifying optimum levels of monetary reinforcement to provide while modeling the ability to resist smoking. Study 2 was designed to validate the model by screening smoking cessation medications with known clinical efficacy. Subjects (n = 62) were randomized to either varenicline 2 mg/day, bupropion 300 mg/day, or placebo, and we then modeled their ability to resist smoking and subsequent ad libitum smoking.
resultsIn Study 1, increasing levels of nicotine deprivation and decreasing levels of monetary reinforcement decreased the ability to resist smoking. In Study 2, the lapse model was found to be sensitive to medication effects among smokers who demonstrated a pattern of heavy, uninterrupted, and automated smoking (i.e., smoked within 5 min of waking). Ratings of craving, mood, withdrawal, and subjective cigarette effects are presented as secondary outcomes with results mirroring clinical findings.
conclusionsOur smoking lapse model demonstrates promise as a translational tool to screen novel smoking cessation medications. Next steps in this line of research will focus on evaluating predictive validity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.